The site marks the latest in a series of expansion programs from the Israeli company and is another move to reinforce its commitment to R&D. The centre will be based near its current location at Migdal HaEmeq. Enzymotec said yesterday that the building was needed to answer a rise in demand for its product, particularly GPC and Krill Oil, which could not be handled by its current facilities. The hub will also be used to produce its "brain energizer" ingredient Sharp PS which is a form of phosphatidylserine, and CardiaBeat, a lipid based ingredient aimed at cardiovascular health. Management and research will also be handled at the building. Dr Ariel Katz, chief executive, said: "During the past four years Enzymotec's activity has grown at a tremendous pace all over the world. "Recent launches of our GPC and Krill oil have turned to be very successful and so our future growth can no longer be sustained by our current infrastructure." Krill Oil is a complex of marine-derived Omega-3 DHA and EPA. GPC is aimed at improving mental and cognitive abilities, and is an alpha-Glycerol PhosphatidylCholine. Enzymotec was not available for further comment prior to publication, and it is not yet known the size of its current facilities, or by how much the new centre will increase production. In December it unveiled a research and development budget for this year of €2.5m. The announcement added further testament to the company's strong focus on science, which planned for four clinical trials to be carried out this year. In 2005 Enzymotec production capacity was increased by one third. Three more expansions were announced last year at its phospholipids plant. This was said to be spurred by growing awareness of its new ingredients in the mental and cognitive category. This summer Enzymotec and Swedish specialty oil and fat manufacturer AarhusKarlshamn (AAK) entered into a joint venture to deliver advanced lipids to the food industry - starting with InFat for infant formulas and working towards ingredients for functional foods.